Artiva Biotherapeutics shares rise on positive arthritis trial data
Updated
Updated · MarketWatch · May 8
Artiva Biotherapeutics shares rise on positive arthritis trial data
5 articles · Updated · MarketWatch · May 8
The stock gained 11% to $13.92 premarket after initial data showed a 71% response rate in rheumatoid arthritis patients with at least six months of follow-up.
Artiva said no patients relapsed or needed new immunomodulatory drugs, and the AlloNK-plus-rituximab regimen was tolerable enough to support outpatient use in community rheumatology settings.
After meeting the FDA, the company plans a 150-patient phase 3 registrational trial in late 2026, with efficacy data due in 2028 and a potential licence application in 2029.
With a 71% response rate, can Artiva’s therapy overcome the hurdles of long-term safety and high cost in the crowded arthritis market?
Artiva’s single trial approval signals a major FDA policy shift. Does this new fast-track approach prioritize drug development speed over patient safety?
In the race for an autoimmune cure, will 'off-the-shelf' NK cells prove more successful than complex, engineered CAR-T therapies?